These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31347066)

  • 1. Mass Spectrometry for the Study of Autism and Neurodevelopmental Disorders.
    Wormwood KL; Ngounou Wetie AG; Ryan JP; Darie CC; Woods AG
    Adv Exp Med Biol; 2019; 1140():477-499. PubMed ID: 31347066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass spectrometry for the study of autism and neurodevelopmental disorders.
    Ngounou Wetie AG; Dekroon RM; Mocanu M; Ryan JP; Darie CC; Woods AG
    Adv Exp Med Biol; 2014; 806():525-44. PubMed ID: 24952201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autism spectrum disorder: an omics perspective.
    Woods AG; Wormwood KL; Wetie AG; Aslebagh R; Crimmins BS; Holsen TM; Darie CC
    Proteomics Clin Appl; 2015 Feb; 9(1-2):159-68. PubMed ID: 25311756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolated autism is not an indication for Smith-Lemli-Opitz syndrome biochemical testing.
    Kaub PA; Sharp PC; Ranieri E; Fletcher JM
    J Paediatr Child Health; 2022 Apr; 58(4):630-635. PubMed ID: 34773316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and Predictors of Anxiety Disorders in Adolescent and Adult Males with Autism Spectrum Disorder and Fragile X Syndrome.
    Ezell J; Hogan A; Fairchild A; Hills K; Klusek J; Abbeduto L; Roberts J
    J Autism Dev Disord; 2019 Mar; 49(3):1131-1141. PubMed ID: 30430320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol alterations in fragile X syndrome, autism spectrum disorders and other neurodevelopmental disorders.
    Benachenhou S; Laroui A; Dionne O; Rojas D; Toupin A; Çaku A
    Int Rev Neurobiol; 2023; 173():115-139. PubMed ID: 37993175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autism Spectrum Disorder in Fragile X Syndrome: Cooccurring Conditions and Current Treatment.
    Kaufmann WE; Kidd SA; Andrews HF; Budimirovic DB; Esler A; Haas-Givler B; Stackhouse T; Riley C; Peacock G; Sherman SL; Brown WT; Berry-Kravis E
    Pediatrics; 2017 Jun; 139(Suppl 3):S194-S206. PubMed ID: 28814540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gaze avoidance and perseverative language in fragile X syndrome and autism spectrum disorder: brief report.
    Friedman L; Sterling A; Barton-Hulsey A
    Dev Neurorehabil; 2018 Feb; 21(2):137-140. PubMed ID: 29333915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melatonin as a Novel Interventional Candidate for Fragile X Syndrome with Autism Spectrum Disorder in Humans.
    Won J; Jin Y; Choi J; Park S; Lee TH; Lee SR; Chang KT; Hong Y
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28632163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autism in Fragile X Syndrome; A Functional MRI Study of Facial Emotion-Processing.
    McKechanie AG; Campbell S; Eley SEA; Stanfield AC
    Genes (Basel); 2019 Dec; 10(12):. PubMed ID: 31861230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Pilot Proteomic Analysis of Salivary Biomarkers in Autism Spectrum Disorder.
    Ngounou Wetie AG; Wormwood KL; Russell S; Ryan JP; Darie CC; Woods AG
    Autism Res; 2015 Jun; 8(3):338-50. PubMed ID: 25626423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autism Symptoms in Fragile X Syndrome.
    Niu M; Han Y; Dy ABC; Du J; Jin H; Qin J; Zhang J; Li Q; Hagerman RJ
    J Child Neurol; 2017 Sep; 32(10):903-909. PubMed ID: 28617074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visuo-spatial construction trajectories in Fragile X Syndrome (FXS) and Autism Spectrum Disorders (ASD): Evidence of cognitive heterogeneity within neurodevelopmental conditions.
    Ballantyne CJ; Núñez M; Manoussaki K
    Res Dev Disabil; 2017 Nov; 70():113-125. PubMed ID: 28923376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholesterol metabolism pathway in autism spectrum disorder: From animal models to clinical observations.
    Lin J; de Rezende VL; de Aguiar da Costa M; de Oliveira J; Gonçalves CL
    Pharmacol Biochem Behav; 2023 Feb; 223():173522. PubMed ID: 36717034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioral phenotype of RSH/Smith-Lemli-Opitz syndrome.
    Tierney E; Nwokoro NA; Kelley RI
    Ment Retard Dev Disabil Res Rev; 2000; 6(2):131-4. PubMed ID: 10899806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contrasting age related changes in autism spectrum disorder phenomenology in Cornelia de Lange, Fragile X, and Cri du Chat syndromes: Results from a 2.5 year follow-up.
    Cochran L; Moss J; Nelson L; Oliver C
    Am J Med Genet C Semin Med Genet; 2015 Jun; 169(2):188-97. PubMed ID: 25989416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neurochemical basis for the treatment of autism spectrum disorders and Fragile X Syndrome.
    Hampson DR; Adusei DC; Pacey LK
    Biochem Pharmacol; 2011 May; 81(9):1078-86. PubMed ID: 21333634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward an understanding of the role of the exposome on fragile X phenotypes.
    Westmark CJ
    Int Rev Neurobiol; 2023; 173():141-170. PubMed ID: 37993176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Proteomics Investigation of Salivary Profiles as Potential Biomarkers for Autism Spectrum Disorder (ASD).
    Wormwood KL; Charette L; Ryan JP; Darie CC; Woods AG
    Protein J; 2023 Oct; 42(5):607-620. PubMed ID: 37566278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A proteomic analysis of urine biomarkers in autism spectrum disorder.
    Wang Y; Zhang J; Song W; Tian X; Liu Y; Wang Y; Ma J; Wang C; Yan G
    J Proteomics; 2021 Jun; 242():104259. PubMed ID: 33957315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.